Rutgers Entrepreneurs: Meet the CEO of Infinity Biologix, Pioneer of COVID-19 Saliva Test

In April, Infinity Biologix developed the first COVID-19 saliva test to receive emergency use authorization by the U.S. Food and Drug Administration. Pavita Howe, director of Entrepreneurship Partnerships at Rutgers’ Corporate Engagement Center, will talk with Andrew Brooks, CEO of the company, on the evolution of Rutgers’ RUCDR Infinite Biologics, how it launched a new company, and how it developed its COVID-19 saliva test.

This event is co-sponsored by Rutgers Entrepreneurs – Corporate Engagement Center and the RUAA.